Bacterin’s OsteoSponge® Product Generates Positive Clinical Results
BELGRADE, Mont.--(BUSINESS WIRE)--
Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the
development of revolutionary bone graft material and antimicrobial
coatings for medical applications, announces that the first clinical
results using the OsteoSponge product for foot and ankle
arthrodesis have been published in
. The article reports a multi-center, retrospective analysis
of 80 joint fusions in 47 subjects who had undergone foot and ankle
fusion procedures utilizing OsteoSponge bone graft. Overall, a fusion
rate of 97.5% (78 of 80 joints) was determined by radiographic analysis.
The article, titled A Retrospective Analysis Evaluating Allogeneic
Cancellous Bone Sponge for Foot and Ankle Arthrodesis, reported
comparable or greater foot and ankle fusion rates, as judged
radiographically, to that reported in the biomedical literature.
Additionally, at 12-month post-operative assessment, the authors
observed statistically significant improvements in function and pain
alleviation at rates greater than those previously reported in
The data published in
serve as yet another testament to the efficacy of the OsteoSponge
product, said Guy Cook, Bacterins CEO. We believe these results will
aid in our goal of expanding Bacterins presence in the foot and ankle
bone grafting market and are consistent with Bacterins mission of
helping our surgeon users provide the best clinical outcomes for their
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops,
manufactures and markets biologics products to domestic and
international markets. Bacterin's proprietary methods optimize the
growth factors in human allografts to create the ideal stem cell
scaffold to promote bone, subchondral repair and dermal growth. These
products are used in a variety of applications including enhancing
fusion in spine surgery, relief of back pain, promotion of bone growth
in foot and ankle surgery, promotion of cranial healing following
neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops, employs, and licenses
bioactive coatings for various medical device applications. Bacterin's
strategic coating initiatives include antimicrobial coatings designed to
inhibit biofilm formation and microbial contamination. For further
information, please visit www.bacterin.com.
This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that are subject to significant risks and
uncertainties. Forward-looking statements include statements that are
predictive in nature, that depend upon or refer to future events or
conditions, or that include words such as "continue," "efforts,"
"expects," "anticipates," "intends," "plans," "believes," "estimates,"
"projects," "forecasts," "strategy," "will," "goal," "target,"
"prospects," "potential," "optimistic," "confident," "likely,"
"probable" or similar expressions or the negative thereof. Statements of
historical fact also may be deemed to be forward-looking statements. We
caution that these statements by their nature involve risks and
uncertainties, and actual results may differ materially depending on a
variety of important factors, including, among others: the Company's
ability to launch beta and full product releases, the Company's ability
to obtain FDA concurrence use for anti-microbial coatings in a timely
manner; the Company's ability to meet its obligations under existing and
anticipated contractual obligations; the Company's ability to develop,
market, sell and distribute desirable applications, products and
services and to protect its intellectual property; the ability of the
Company's sales force to achieve expected results; the ability of the
Company's customers to pay and the timeliness of such payments,
particularly during recessionary periods; the Company's ability to
obtain financing as and when needed; changes in consumer demands and
preferences; the Company's ability to attract and retain management and
employees with appropriate skills and expertise; the impact of increased
taxation, changes in market, legal and regulatory conditions and in the
applicable business environment, including actions of competitors; and
other factors. Additional risk factors are listed in the Company's
Annual Report on Form 10-K under the heading "Risk Factors." The Company
undertakes no obligation to release publicly any revisions to any
forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events, except
as required by law.
For Bacterin International Holdings, Inc.COCKRELL GROUPRich
CockrellNY: 212.521.4138ATL: email@example.com
Source: Bacterin International Holdings, Inc.